SCHEMBL5111914

SCHEMBL5111914

COc1ccccc1C(=O)Nc1c[nH]nc1-c1nc2c([nH]1)CCN(C)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 10/20 0.44
HTR1A P08908 1/20 0.43
HTR1B P28222 1/20 0.43
HTR1F P30939 1/20 0.43
RAB9A P51151 3/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 2/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
GPR35 Q9HC97 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
BRD4 O60885 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5111809 0.89 MAPK1 (0.42) BRPF1HTR1AHTR1BHTR1FRAB9A
SCHEMBL5098938 0.88 ATR (0.40) BRPF1HTR1AHTR1BHTR1FRAB9A
SCHEMBL5106436 0.86 ABL1 (0.43) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL5104896 0.86 MAPT (0.38) BRPF1HTR1AHTR1BHTR1FRAB9A
SCHEMBL5111561 0.83 RAB9A (0.43) BRPF1RAB9AMAPTNPC1ADORA3
SCHEMBL5112753 0.81 PDCD1 (0.39) MEN1KMT2APOLB
SCHEMBL5105549 0.81 HTR1F (0.39) BRPF1HTR1AHTR1BHTR1FRAB9A
SCHEMBL5102502 0.78 HTR1F (0.43) HTR1AHTR1BHTR1F
SCHEMBL22236261 0.77 ROCK2 (0.38) HTR1AHTR1BHTR1FMAPTPOLB
SCHEMBL8302251 0.77 FOXO1 (0.64) RAB9AMAPTNPC1ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors CDK3, CDK1, GSK3B BRPF1 3587/4885HTR1A 3049/4885HTR1B 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.